Skip to main content

Advertisement

SpringerLink
Log in

Immune-Mediated Neuropathies

  • Neuromuscular Disorders (C Fournier, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

The purpose of this review article is to discuss the pathogenesis of acute and chronic immune-mediated neuropathies along with the recent advances in their treatment.

Recent findings

Since the first description of Guillain-Barre syndrome (GBS) more than a century ago, there have been numerous forms of immune-mediated neuropathies described expanding the spectrum. Understanding the role of the immune system in the pathogenesis of immune-mediated neuropathies has been an advancement towards the diagnosis and treatment.

Summary

It is postulated that immune-mediated neuropathies are a group of diseases resulting from autoimmunity towards multiple components of peripheral nervous system. These have a wide range of pathologic mechanisms, defined clinical presentations, electro-diagnostic and laboratory findings which help in diagnosis and management. Although immunosuppression is the common modality of treatment for these disorders, uncovering distinct pathogenic mechanisms can allow for targeted immunomodulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Barohn RJ. Approach to peripheral neuropathy and neuronopathy. Semin Neurol. 1998;18:7–18.

    Article  CAS  PubMed  Google Scholar 

  2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet. 2016;388:717–27.

    Article  PubMed  Google Scholar 

  3. •• Esposito S, Longo MR. Guillain-Barre syndrome. Autoimmun Rev. 2017;16:96–101. This review summarises the clinical features and diagnostic criteria of GBS and proposes the algorithm for management.

    Article  PubMed  Google Scholar 

  4. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 Suppl:S21–4.

    Article  CAS  PubMed  Google Scholar 

  5. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82.

    Article  PubMed  CAS  Google Scholar 

  6. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130–6.

    Article  CAS  PubMed  Google Scholar 

  7. •• Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015;1852:658–66. This article reviews the pathogenesis of GBS, CIDP, MMN and anti-MAG neuropathy.

    Article  CAS  PubMed  Google Scholar 

  8. •• Kieseier BC, Mathey EK, Sommer C, Hartung H-P. Immune-mediated neuropathies. Nat Rev Dis Prim. 2018;4:31. This is a recent comprehensive review paper on pathogenesis, diagnosis and management of AIDP, CIDP and MMN.

    Article  PubMed  Google Scholar 

  9. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch Neurol. 2001;58:893–8.

    Article  CAS  PubMed  Google Scholar 

  10. Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH, Jacobs BC, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75:1439–47.

    Article  CAS  PubMed  Google Scholar 

  11. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology. 1985;35:1096 LP–1096.

    Article  Google Scholar 

  12. van der Meché FGA, Schmitz PIM. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123–9.

    Article  PubMed  Google Scholar 

  13. Hughes RAC, Swan A V, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2014;CD002063.

  14. Hughes RAC, Swan AV, Raphaël J-C, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–57.

    Article  PubMed  Google Scholar 

  15. Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Ther Apher. 1997;1:129–30.

    Article  CAS  PubMed  Google Scholar 

  16. Hughes RAC, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016.

  17. Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, et al. Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22:4–12.

    Article  CAS  PubMed  Google Scholar 

  18. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17:519–29.

    Article  CAS  PubMed  Google Scholar 

  19. Herbison GJ, Jaweed MM, Ditunno JFJ. Exercise therapies in peripheral neuropathies. Arch Phys Med Rehabil. 1983;64:201–5.

    CAS  PubMed  Google Scholar 

  20. Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66:677–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mathey EK, Park SB, Hughes RAC, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973–85.

    Article  PubMed  Google Scholar 

  22. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615–20.

    Article  CAS  PubMed  Google Scholar 

  23. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982;32:958–64.

    Article  CAS  PubMed  Google Scholar 

  24. Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculopathy. Neurology. 2004;63:1662–9.

    Article  CAS  PubMed  Google Scholar 

  25. Querol L, Illa I. Paranodal and other autoantibodies in chronic inflammatory neuropathies. Curr Opin Neurol. 2015;28:474–9.

    Article  CAS  PubMed  Google Scholar 

  26. Berger M, Allen JA. Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach. Muscle Nerve. 2015;51:315–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17:289–94.

    Article  CAS  PubMed  Google Scholar 

  28. Hughes RAC, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.

    Article  CAS  PubMed  Google Scholar 

  29. • van Schaik IN, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46 Study on SCIg in CIDP.

    Article  PubMed  Google Scholar 

  30. Markvardsen LH, Sindrup SH, Christiansen I, Olsen NK, Jakobsen J, Andersen H. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol. 2017;24:412–8.

    Article  CAS  PubMed  Google Scholar 

  31. Dyck PJ, O’Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–41.

    Article  CAS  PubMed  Google Scholar 

  32. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502.

    Article  CAS  PubMed  Google Scholar 

  33. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:245–53.

    Article  PubMed  CAS  Google Scholar 

  34. Mehndiratta MM, Hughes RAC, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;CD003906.

  35. Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51:1735 LP–1738.

    Article  Google Scholar 

  36. Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856–8.

    Article  CAS  PubMed  Google Scholar 

  37. Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;5:CD003280.

    PubMed  Google Scholar 

  38. Querol L, Rojas-Garcia R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflammation. 2015;2:e149.

    Article  Google Scholar 

  39. Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol. 2010;17:356–63.

    Article  PubMed  Google Scholar 

  40. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76:337–45.

    Article  PubMed  Google Scholar 

  41. Draak THP, Pruppers MHJ, van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC, et al. Grip strength comparison in immune-mediated neuropathies: vigorimeter vs. Jamar. J Peripher Nerv Syst. 2015;20:269–76.

    Article  PubMed  Google Scholar 

  42. Magy L, Chassande B, Maisonobe T, Bouche P, Vallat J-M, Leger J-M. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol. 2003;10:677–85.

    Article  CAS  PubMed  Google Scholar 

  43. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.

    Article  PubMed  Google Scholar 

  44. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.

    Article  CAS  PubMed  Google Scholar 

  45. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993;33:502–6.

    Article  CAS  PubMed  Google Scholar 

  46. Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurol. 2010;12:71–83.

    Article  PubMed  Google Scholar 

  47. Dalakas MC. Rituximab in anti-MAG neuropathy: more evidence for efficacy and more predictive factors. J Neurol Sci. 2017;377:224–6.

    Article  CAS  PubMed  Google Scholar 

  48. •• Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018;11:1756285617746640. Detailed review on anti-MAG neuropathy.

    PubMed  PubMed Central  Google Scholar 

  49. Galassi G, Tondelli M, Ariatti A, Benuzzi F, Nichelli P, Valzania F. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. Int J Neurosci. 2017;127:439–47.

    Article  CAS  PubMed  Google Scholar 

  50. Gazzola S, Delmont E, Franques J, Boucraut J, Salort-Campana E, Verschueren A, et al. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci. 2017;377:144–8.

    Article  CAS  PubMed  Google Scholar 

  51. Rakocevic G, Outschoorn UM, Dalakas M. Obinutuzumab (GAZYVA), a potent anti-B cell agent, in the treatment of rituximab-unresponsive IgM anti-myelin-associated-glycoprotein (MAG)-mediated-neuropathy (P1.450). Neurology. 2018;90:P1.450.

    Article  Google Scholar 

  52. Mauermann ML, Sorenson EJ, Dispenzieri A, Mandrekar J, Suarez GA, Dyck PJ, et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J Neurol Neurosurg Psychiatry. 2012;83:480–6.

    Article  PubMed  Google Scholar 

  53. Li J, Zhang W, Jiao L, Duan M-H, Guan H-Z, Zhu W-G, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood. 2011;117:6445–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood. 2005;106:1135.

    Article  CAS  PubMed  Google Scholar 

  55. Chu BF, Shana’ah A, Hofmeister CC, Benson DM, Sell M, Tucker J, et al. Long-term therapy with lenalidomide in a patient with POEMS syndrome. Eur J Case Rep Intern Med. 2014;1:2014_000093.

    PubMed  Google Scholar 

  56. Guimaraes-Costa R, Bombelli F, Leger J-M. Multifocal motor neuropathy. Curr Opin Neurol. 2013;26:503–9.

    Article  CAS  PubMed  Google Scholar 

  57. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol. 2000;57:109–13.

    Article  CAS  PubMed  Google Scholar 

  58. Vlam L, van den Berg LH, Cats EA, Piepers S, van der Pol W-L. Immune pathogenesis and treatment of multifocal motor neuropathy. J Clin Immunol. 2013;33(Suppl 1):S38–42.

    Article  PubMed  CAS  Google Scholar 

  59. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591–625.

    Article  PubMed  Google Scholar 

  60. Uncini A, Santoro M, Corbo M, Lugaresi A, Latov N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve. 1993;16:610–5.

    Article  CAS  PubMed  Google Scholar 

  61. Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol. 1995;37:436–42.

    Article  CAS  PubMed  Google Scholar 

  62. Kiernan MC, Guglielmi J, Kaji R, Murray NMF, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain. 2002;125:664–75.

    Article  PubMed  Google Scholar 

  63. Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry. 2015;86:1186–95.

    Article  PubMed  Google Scholar 

  64. van Schaik IN, Léger JM, Nobile-Orazio E, Cornblath DR, Hadden RD, Koski CL, et al. European Federation of Neurological Societies/peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revisi. J Peripher Nerv Syst. 2010;15:295–301.

    Article  Google Scholar 

  65. Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology. 1998;50:1480–2.

    Article  CAS  PubMed  Google Scholar 

  66. Cocito D, Merola A, Romagnolo A, Peci E, Toscano A, Mazzeo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry. 2016;87:791–3.

    Article  PubMed  Google Scholar 

  67. Kamiya-Matsuoka C, Shroff S, Gildersleeve K, Hormozdi B, Manning JT, Woodman KH. Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes. J Neurol Sci. 2014;343:144–8.

    Article  PubMed  Google Scholar 

  68. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67:330–5.

    Article  PubMed  Google Scholar 

  69. Gwathmey KG. Sensory neuronopathies. Muscle Nerve. 2016;53:8–19.

    Article  PubMed  Google Scholar 

  70. Darnell RB. Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Arch Neurol. 2004;61:30–2.

    Article  PubMed  Google Scholar 

  71. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol. 2005;18:598–603.

    Article  PubMed  Google Scholar 

  72. Antoine JC, Honnorat J, Camdessanche JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49:214–21.

    Article  CAS  PubMed  Google Scholar 

  73. Muppidi S, Vernino S. Paraneoplastic neuropathies. Continuum (Minneap Minn). 2014;20:1359–72.

    Google Scholar 

  74. Koike H, Sobue G. Paraneoplastic neuropathy. Handb Clin Neurol. 2013;115:713–26.

    Article  PubMed  Google Scholar 

  75. Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.

    Article  CAS  PubMed  Google Scholar 

  76. Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. Lancet Neurol. 2014;13:67–82.

    Article  PubMed  Google Scholar 

  77. Gorson KC. Therapy for vasculitic neuropathies. Curr Treat Options Neurol. 2006;8:105–17.

    Article  PubMed  Google Scholar 

  78. Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003;62:1221–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.

    Article  PubMed  CAS  Google Scholar 

  80. Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother. 2015;38:77–9.

    Article  PubMed  PubMed Central  Google Scholar 

  81. de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375:296–7.

    Article  PubMed  Google Scholar 

  82. Uyanikoglu A, Ermis F, Akyuz F, Pinarbasi B, Baran B, Aydogan T, et al. Infliximab in inflammatory bowel disease: attention to adverse events. Eur Rev Med Pharmacol Sci. 2014;18:2337–42.

    CAS  PubMed  Google Scholar 

  83. Seo B, Jeong YJ, Hong S, Kim Y-G, Lee C-K, Yoo B. A case of infliximab-induced multifocal motor neuropathy in a patient with rheumatoid arthritis and literature review. J Rheum Dis. 2016;23:250–5.

    Article  Google Scholar 

  84. Stubgen J-P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281–92.

    Article  CAS  PubMed  Google Scholar 

  85. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Houston Methodist Neurological Institute, 6560 Fannin Street, Ste 802, Houston, TX, 77030, USA

    Mithila Fadia MD, Sheetal Shroff MD & Ericka Simpson MD

Authors
  1. Mithila Fadia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheetal Shroff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ericka Simpson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ericka Simpson MD.

Ethics declarations

Conflict of Interest

Mithila Fadia and Sheetal Shroff each declare no potential conflicts of interest. Ericka Simpson has served on the speaker bureau for indications for subcutaneous IgG in CIDP patients sponsored by CSL Behring, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuromuscular Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fadia, M., Shroff, S. & Simpson, E. Immune-Mediated Neuropathies. Curr Treat Options Neurol 21, 28 (2019). https://doi.org/10.1007/s11940-019-0569-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-019-0569-y

Keywords

Search

Navigation